Risk of second primary malignancies and survival of adult patients with polycythemia vera: A United States population-based retrospective study

Nabin Khanal, Smith Giri, Smrity Upadhyay, Valerie K. Shostrom, Ranjan Pathak, Vijaya R Bhatt

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Although the median survival in polycythemia vera (PV) is 14 years, mortality is higher than in an age- and sex-matched population. This study included 3941 PV patients diagnosed between 2000-2012 from Surveillance, Epidemiology and End Results (SEER) 13 registry to determine 5-year survival and the incidence of second primary malignancies (SPM). The actuarial 5 year survival in the overall cohort was 79.5%. The cumulative incidence of SPM was 13.1% at 10 years. SPMs occurred at a standardized incidence ratio (SIR) of 1.29 (95% CI = 1.16-1.43; p < 0.001) with an absolute excess risk (AER) of 42.49 per 10 000 population. A significantly higher risk was noted for acute myeloid leukemia (SIR = 12.24; 95% CI = 8.17-17.8; p-value < 0.001) and chronic myeloid leukemia (SIR = 10.66; 95% CI = 3.75-19.6; p-value < 0.001). Patients with PV are at a high risk of SPM and leukemic transformation, which may compromise long-term survival.

Original languageEnglish (US)
Pages (from-to)129-133
Number of pages5
JournalLeukemia and Lymphoma
Volume57
Issue number1
DOIs
StatePublished - Jan 2 2016

Fingerprint

Polycythemia Vera
Second Primary Neoplasms
Retrospective Studies
Survival
Incidence
Population
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Acute Myeloid Leukemia
Registries
Epidemiology
Mortality

Keywords

  • Polycythemia vera
  • leukemic transformation
  • second primary malignancy
  • survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Risk of second primary malignancies and survival of adult patients with polycythemia vera : A United States population-based retrospective study. / Khanal, Nabin; Giri, Smith; Upadhyay, Smrity; Shostrom, Valerie K.; Pathak, Ranjan; Bhatt, Vijaya R.

In: Leukemia and Lymphoma, Vol. 57, No. 1, 02.01.2016, p. 129-133.

Research output: Contribution to journalArticle

Khanal, Nabin ; Giri, Smith ; Upadhyay, Smrity ; Shostrom, Valerie K. ; Pathak, Ranjan ; Bhatt, Vijaya R. / Risk of second primary malignancies and survival of adult patients with polycythemia vera : A United States population-based retrospective study. In: Leukemia and Lymphoma. 2016 ; Vol. 57, No. 1. pp. 129-133.
@article{c74b1731bc9b4b55bea6c509f9821f5e,
title = "Risk of second primary malignancies and survival of adult patients with polycythemia vera: A United States population-based retrospective study",
abstract = "Although the median survival in polycythemia vera (PV) is 14 years, mortality is higher than in an age- and sex-matched population. This study included 3941 PV patients diagnosed between 2000-2012 from Surveillance, Epidemiology and End Results (SEER) 13 registry to determine 5-year survival and the incidence of second primary malignancies (SPM). The actuarial 5 year survival in the overall cohort was 79.5{\%}. The cumulative incidence of SPM was 13.1{\%} at 10 years. SPMs occurred at a standardized incidence ratio (SIR) of 1.29 (95{\%} CI = 1.16-1.43; p < 0.001) with an absolute excess risk (AER) of 42.49 per 10 000 population. A significantly higher risk was noted for acute myeloid leukemia (SIR = 12.24; 95{\%} CI = 8.17-17.8; p-value < 0.001) and chronic myeloid leukemia (SIR = 10.66; 95{\%} CI = 3.75-19.6; p-value < 0.001). Patients with PV are at a high risk of SPM and leukemic transformation, which may compromise long-term survival.",
keywords = "Polycythemia vera, leukemic transformation, second primary malignancy, survival",
author = "Nabin Khanal and Smith Giri and Smrity Upadhyay and Shostrom, {Valerie K.} and Ranjan Pathak and Bhatt, {Vijaya R}",
year = "2016",
month = "1",
day = "2",
doi = "10.3109/10428194.2015.1071492",
language = "English (US)",
volume = "57",
pages = "129--133",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Risk of second primary malignancies and survival of adult patients with polycythemia vera

T2 - A United States population-based retrospective study

AU - Khanal, Nabin

AU - Giri, Smith

AU - Upadhyay, Smrity

AU - Shostrom, Valerie K.

AU - Pathak, Ranjan

AU - Bhatt, Vijaya R

PY - 2016/1/2

Y1 - 2016/1/2

N2 - Although the median survival in polycythemia vera (PV) is 14 years, mortality is higher than in an age- and sex-matched population. This study included 3941 PV patients diagnosed between 2000-2012 from Surveillance, Epidemiology and End Results (SEER) 13 registry to determine 5-year survival and the incidence of second primary malignancies (SPM). The actuarial 5 year survival in the overall cohort was 79.5%. The cumulative incidence of SPM was 13.1% at 10 years. SPMs occurred at a standardized incidence ratio (SIR) of 1.29 (95% CI = 1.16-1.43; p < 0.001) with an absolute excess risk (AER) of 42.49 per 10 000 population. A significantly higher risk was noted for acute myeloid leukemia (SIR = 12.24; 95% CI = 8.17-17.8; p-value < 0.001) and chronic myeloid leukemia (SIR = 10.66; 95% CI = 3.75-19.6; p-value < 0.001). Patients with PV are at a high risk of SPM and leukemic transformation, which may compromise long-term survival.

AB - Although the median survival in polycythemia vera (PV) is 14 years, mortality is higher than in an age- and sex-matched population. This study included 3941 PV patients diagnosed between 2000-2012 from Surveillance, Epidemiology and End Results (SEER) 13 registry to determine 5-year survival and the incidence of second primary malignancies (SPM). The actuarial 5 year survival in the overall cohort was 79.5%. The cumulative incidence of SPM was 13.1% at 10 years. SPMs occurred at a standardized incidence ratio (SIR) of 1.29 (95% CI = 1.16-1.43; p < 0.001) with an absolute excess risk (AER) of 42.49 per 10 000 population. A significantly higher risk was noted for acute myeloid leukemia (SIR = 12.24; 95% CI = 8.17-17.8; p-value < 0.001) and chronic myeloid leukemia (SIR = 10.66; 95% CI = 3.75-19.6; p-value < 0.001). Patients with PV are at a high risk of SPM and leukemic transformation, which may compromise long-term survival.

KW - Polycythemia vera

KW - leukemic transformation

KW - second primary malignancy

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84954391907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954391907&partnerID=8YFLogxK

U2 - 10.3109/10428194.2015.1071492

DO - 10.3109/10428194.2015.1071492

M3 - Article

C2 - 26159045

AN - SCOPUS:84954391907

VL - 57

SP - 129

EP - 133

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1

ER -